References
- Syed, S.; Rowinsky, E. The new generation of targeted therapies for breast cancer.Oncology (Huntingt.) 2003, 17, 1339–1351. [CSA]
- Augen, J. Bioinformatics and data mining in suuport of drug discovery. In Handbook of Anticancer Drug Development; Budman, D R., Calvert, A., Rowinsky, E., Eds.; Lippincott Williams and Wilkins: Baltimore, 2004; 79–96.
- DiMasi, J A.; Hansen, R W.; Grabowski, H G. The price of innovation: new estimates of drug development costs.J. Health Econ. 2003, 22, 151–185. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Pellegrini, F.; Budman, D R. Review: tubulin function, action of antitubulin drugs, and new drug development.Cancer Investig. 2005, 23, 264–273. [CSA]
- Jordan, M A.; Wendell, K.; Gardiner, S.; Derry, W B.; Copp, H.; Wilson, L. Itotic block induced in HeLa cells by low concentrations of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death.Cancer Res. 1996, 56, 816–825. [PUBMED], [INFOTRIEVE], [CSA]
- Liu, X M.; Wang, L G.; Kreis, W.; Budman, D R.; Adams, L M. Differential effect of vinorelbine versus paclitaxel on ERK2 kinase activity during apoptosis in MCF-7 cells.Br. J. Cancer 2001, 85, 1403–1411. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Knick, V.; Eberwein, D.; Miller, C. Vinorelbine tartrate and paclitaxel combinations: enhanced activity against in vivo P388 murine leukemia cells.J. Natl. Cancer Inst. 1995, 87, 1072–1077. [PUBMED], [INFOTRIEVE], [CSA]
- Budman, D R.; Calabro, A. In vitro search for synergy and antagonism: evaluation of docetaxel combinations in breast cancer cell lines.Breast Cancer Res. 2002, 74, 41–46. [CSA], [CROSSREF]
- Grunberg, S M.; Dugan, M C.; Greenblatt, M S. Phase I/II trial of paclitaxel and vinorelbine in advanced non-small cell lung cancer.Cancer Investig. 2005, 23. [CSA]
- Jung, M K.; Grunberg, S.; Timblin, C.; Buder-Hoffman, S.; Vacek, P.; Taatjes, D. Paclitaxel and vinorelbine cause synergistic increases in apoptosis, not in microtubular disruption in human lung adenocarcinoma A-549.Histochem. Cell Biol. 2004, 12, 115–121. [CSA], [CROSSREF]
- Strathopoulos, G.; Veslemes, M.; Georgatou, N.; Antoniou, D.; Giamboudakis, P.; Katis, K.; Tsavdaridis, D.; Rigatos, S.; Dimitroulis, I.; Bastani, S.; Loukides, S.; Vergos, K.; Marossis, K.; Grigoratou, T.; Kalatzi, E.; Charalambatou, M.; Paspalli, A.; Michalopoulou, P.; Stoka, M.; Gerogianni, A. Front-line paclitaxel-vinorelbine versus paclitaxel-carboplatin in patients with advanced non-small cell lung cancer: a randomized phase III trial.Ann. Oncol. 2004, 15, 1048–1055. [CSA], [CROSSREF]
- Cohen, R.; Mueller, S.; Haden, K.; de Souza, P. Phase I study of weekly vinorelbine in combination with weekly paclitaxel in adult patients with advanced refractory cancer.Cancer Investig. 2000, 18, 422–428. [CSA]